tetano
Editor, Senior Moderator
ChemMedChem
. 2026 Aug 27;21(16):e70448.
doi: 10.1002/cmdc.70448.
Ifigeneia Akrani 1 , Haifa El Kilani 2 , Franck Touret 3 , Sophia Kouvali 1 , Veronika Gourni 1 , Aggeliki Tsoka 4 , Joulia K Tsetis 5 , Constantinos Vorgias 4 , Rolf Hilgenfeld 2 , Ioannis K Kostakis 1 , Vassilios Myrianthopoulos 1 , Emmanuel Mikros 1 6
Affiliations
Regardless of the massive global efforts to combat the virus causing SARS-CoV-2 syndrome, the infection remains a substantial health challenge worldwide in the years following 2019. To this direction, targeting the main viral protease Mpro has been proposed as a tractable and particularly promising approach toward developing effective and safe COVID-19 antivirals. By applying an integrated workflow combining a previously developed in silico consensus ranking protocol with two orthogonal in vitro methods, the NCI/DTP repository is screened and the discovery of an original naphthol scaffold with Mpro inhibitory properties is reported. The hit is characterized in terms of structure and binding thermodynamics by combining X-ray crystallography and isothermal titration calorimetry where a binding affinity constant of 1.55 μM is determined. The compound is further evaluated against virus-infected cells, where an EC50 value of 7.23 μM and comparable toxicity with nirmatrelvir are measured. Chemical synthesis is additionally employed to facilitate optimal exploration of the structure-activity relationship landscape regarding the new hit. By integrating computational, biophysical, and enzymatic methods, the suggested approach allows the combination of a structural hypothesis with functional evidence and shows its capacity toward identifying and rationally optimizing structurally original noncovalent Mpro inhibitors.
Keywords: antiviral agents; biophysics; consensus screening; molecular simulations; naphthols.
. 2026 Aug 27;21(16):e70448.
doi: 10.1002/cmdc.70448.
Investigating the Binding Mode of a Naphthol-Based Inhibitor Targeting SARS-CoV-2 Main Protease
Ifigeneia Akrani 1 , Haifa El Kilani 2 , Franck Touret 3 , Sophia Kouvali 1 , Veronika Gourni 1 , Aggeliki Tsoka 4 , Joulia K Tsetis 5 , Constantinos Vorgias 4 , Rolf Hilgenfeld 2 , Ioannis K Kostakis 1 , Vassilios Myrianthopoulos 1 , Emmanuel Mikros 1 6
Affiliations
- PMID: 42647061
- DOI: 10.1002/cmdc.70448
Abstract
Regardless of the massive global efforts to combat the virus causing SARS-CoV-2 syndrome, the infection remains a substantial health challenge worldwide in the years following 2019. To this direction, targeting the main viral protease Mpro has been proposed as a tractable and particularly promising approach toward developing effective and safe COVID-19 antivirals. By applying an integrated workflow combining a previously developed in silico consensus ranking protocol with two orthogonal in vitro methods, the NCI/DTP repository is screened and the discovery of an original naphthol scaffold with Mpro inhibitory properties is reported. The hit is characterized in terms of structure and binding thermodynamics by combining X-ray crystallography and isothermal titration calorimetry where a binding affinity constant of 1.55 μM is determined. The compound is further evaluated against virus-infected cells, where an EC50 value of 7.23 μM and comparable toxicity with nirmatrelvir are measured. Chemical synthesis is additionally employed to facilitate optimal exploration of the structure-activity relationship landscape regarding the new hit. By integrating computational, biophysical, and enzymatic methods, the suggested approach allows the combination of a structural hypothesis with functional evidence and shows its capacity toward identifying and rationally optimizing structurally original noncovalent Mpro inhibitors.
Keywords: antiviral agents; biophysics; consensus screening; molecular simulations; naphthols.